MedTrace Logo

Safety Study of Topical Human FGF-1 for Wound Healing

NCT00916292 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2012-03-12

No results posted yet for this study

Summary

The purpose of the study is to see if FGF-1 is safe when applied topically to the surface of a wound.

Conditions

  • Diabetic Foot Ulcers

Interventions

DRUG

FGF-1 141

Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.

DRUG

FGF-1 141

Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.

Sponsors & Collaborators

  • Phage Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Shawn Searle, MD · Dedicated Phase I

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00916292 on ClinicalTrials.gov